In line with the FDA initiative of quality by design GEA Pharma Systems introduces its ConsiGma continuous tableting system. The system satisfies the pharmaceutical industry’s demand for continuous production to provide improved quality, flexibility and consistency for pharmaceutical processes.
One ConsiGma can run 500 g in R&D, but can also run clinical trial, launch size, and any production size batches. There is no process scale-up as time is the only relevant factor in a continuous process. This allows manufacturers to reduce development time dramatically to reduce costs and bring products to market much faster.
The system is compact, has a modular construction allowing it to fit into any R&D department or existing tablet production room. After a simple start-up period it’s ready to go. Installation time and cost are reduced and it’s also possible to avoid high peak energy periods and run at continuous low energy consumption, helping companies meet their environmental obligations.
Online-Info www.cpp-net.com/2310441
Share:
